Winding – tensioning – or guiding – Reeling device – Fishing rod reel
Reexamination Certificate
2007-09-18
2007-09-18
Nickol, Gary B. (Department: 1647)
Winding, tensioning, or guiding
Reeling device
Fishing rod reel
Reexamination Certificate
active
10752869
ABSTRACT:
Methods for treating kinesia (motion sickness) by local administration of a Clostridial toxin, such as abotulinumtoxin, to a cranial or neck area of a patient susceptible to motion sickness.
REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6265379 (2001-07-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358926 (2002-03-01), Donovan
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
Wenzel R.G., Am J Health Syst Pharm. 2004, vol. 61(22 Suppl 6): S5-10, esp. S6: col. 3, paragraph 4 and S10: col. 2, paragraph 2.
Ansved et al., Neurology May 1997, 48 (5):1440-2, Abstract only.
Billante et al., Muscle & Nerve Sep. 2002 26(3):395-403.
U.S. Appl. No. 10/194,805, filed Jul. 11, 2002, Donovan.
Anderson, T., et al.,Surgical intervention for sinusitis in adults, Curr Allergy Asthma Rep May 2001;1(3):282-8.
Aoki, K., et al.,Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions, Eur J. Neurol 2001: (suppl 5); 21-29.
Aoki, K.,Physiology and pharmacology of therapeutic botulinum neurotoxins, in Kreyden, O., editor, Hyperhydrosis and botulinum toxin in dermatology, Basel, Karger; 2002; 30: pp. 107-116, at 109-110.
Barrientos, N., et al.,Efficacy and safety of butulinum toxin type A(Botox)in the prophylactic treatment of migraine, Headache May 2002;42(5):452.
Bigalke H., et al.,Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission in Mouse Spinal Cord Neurons in Culture, Brain Research 360;318-324:1985.
Bigalke H., et al.,Tetanus Toxin and Botulinum A Toxin Inhibit Release and Uptake of Various Transmitters, as Studied with Particulate Preparations From Rat Brain and Spinal Cord, Naunyn-Schmiedeberg's Arch Pharmacol 316;244-251:1981.
Binz T. et al.,The Complete Sequence of Botulinum Neurotoxin Type A and Comparision with Other Clostridial Neurotoxins, J Biological Chemistry 265(16);9153-9158:1990.
Brem, H., et al,Placebo-Controlled Trial of Safety and Efficacy of Intraoperative Controlled Delivery by Biodegradable Polymers of Chemotherapy for Recurrent GliomasLancet 345:1008-1012:1995.
Brin, M., et al.,Botulinum toxin type A: pharmacology, in Mayer N., editor, Spasticity: etiology, evaluation, management and role of botulinum toxin, 2002; pp. 110-124, at 112-113.
Bushara K.,Botulinum toxin and rhinorrhea, Otolaryngol Head Neck Surg 1996;114(3):507.
Cui, M., et al.,Mechanisms of the antinociceptive effect of subcutaneous BOTOX®: inhibition of peripheral and central nociceptive processing, Naunyn Schmiedebergs Arch Pharmacol 2002; 365 (supp 2): R17.
Duggan et al.;A survey of Botulinum neurotoxin substrate expression in cells; Mov Disord, 10(3):376:1995.
Fung L. K. et al.,Pharmacokinetics of Interstitial Delivery of Carmustine 4-Hydroperoxycyclophosphamide and Paclitaxel From a Biodegradable Polymer Implant in the Monkey Brain, Cancer Research 58;672-684:1998.
Gonelle-Gisprt et al.;Snap -25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion; Biochem J 1;339 (pt 1):159-65:1999.
Guyton A.C. et al.,Textbook of Medical Physiology, W.B. Saunders Company 1996, ninth edition pp. 686-688.
Habermann E., et al.,Tetanus Toxin and Botulinum A and C Neurotoxins Inhibit Noradrenaline Release From Cultured Mouse Brain, J Neurochem 51(2);522-527:1988).
Habermann E.,Inhibition by Tetanus and Botulinum A Toxin of the release of [3H]Noradrenaline and [3H]GABA From Rat Brain Homogenate, Experientia 44;224-226:1988.
Habermann, E.; I-Labeled Neurotoxin from Clostridium Botulinum A: Preparation Binding to Synaptosomes and Ascent to the Spinal Cord;Nauny-Schmiedeberg's Arch. Pharmacol, 1974; 281, 47-56.
Harrison's Principles of Internal Medicine(1998), edited by Anthony Fauci et al., 14th edition, published by McGraw Hill.
Jankovic J. et al.,Therapy With Botulinum Toxin, Marcel Dekker, Inc., (1994), p. 5, 150.
Kohl R., et al.,Motion sickness: a modulatory role of the central cholinergic nervous systemNeuroscience and Biobehavioral Review 7:73-75, 1983.
Kreyden O,Botulinum toxin: From poison to pharmaceutical: The history of a poison that became useful to mankind, Kreyden OP, editor.Hyperhidrosis and Botulinum Toxin in Dermatology. Current Problems in Dermatology: Basel, Karger;2002;30:pp. 94-100.
Mast J., et al.,Successful pain management for Botox injections: A holistic approach, Ann Neurol 2002;52(3):S157.
Miller T., et al.,Botulinum toxin A(Allergan)for chronic intractable headache Equally effective with or without concomitant neck pain, Headache Jun. 2003;43(5):579.
Mittelstaedt H.,Somatic graviception, Biol Psychol 42:53-74, 1996.
Moyer E et al.,Botulinum Toxin Type B: Experimental and Clinical Experience, being chapter 6, pp. 71-85 of “Therapy With Botulinum Toxin”, edited by Jankovic, J. et al. (1994), Marcel Dekker, Inc.
Naumann et al.;Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions; European J. Neurology 6 (Supp 4): S111-S1150:1999.
Oman C.,Motion sickness: a synthesis and evaluation of the sensory conflict theory, Can J Physiol Pharmacol 68:294-303, 1990.
Pearce, L.B.,Pharmacologic Characterization of Botulinum Toxin For Basic Science and Medicine, Toxicon 35(9);1373-1412 at 1393.
Ragona et al.;Management of Parotid Sialocele With Botulinum Toxin; The Laryngoscope109:1344-1346:1999.
Robb N.,The risks of Botox, Harv Womens Health Watch Nov. 2002;10(3):8.
Sanchez-Prieto, J., et al.,Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes, Eur J. Biochem 165;675-681:1897.
Schantz, E.J., et al,Properties and use of Botulinum toxin and Other Microbial Neurotoxins in Medicine, Microbiol Rev. 56;80-99:1992.
Singh,Critical Aspects of Bacterial Protein Toxins, pp. 63-84 (chapter 4) of Natural Toxins II, edited by B.R. Singh et al., Plenum Press, New York (1976).
Sloop et al.;Reconstituted Botulinum toxin type A does not lose potency in humans if it is refrozen or refrigerated for 2 weeks before use; Neurology, 48:249-53:1997.
Wiegand et al. I-Labelled Botulinum A Neurotoxin: Pharmacokinetics inCats after Intramuscular Injection;Nauny-Schmiedeberg's Arch. Pharmacol. 1976; 292, 161-165.
Allergan Inc.
Donovan Stephen
Nassif Claude L.
Nickol Gary B.
Voet Martin A.
LandOfFree
Botulinum toxin treatment for kinesia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum toxin treatment for kinesia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum toxin treatment for kinesia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793893